(Q37975458)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22241590%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

title

Post transplant lymphoproliferative disorders: risk, classification, and therapeutic recommendations (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22241590%20AND%20SRC:MED&resulttype=core&format=json

lymphoproliferative disorders

20 January 2020

main subject

1 reference

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22241590%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

author name string

Deepa Jagadeesh

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22241590%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Bruce A Woda

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22241590%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Jacqueline Draper

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22241590%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

publication date

1 March 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22241590%20AND%20SRC:MED&resulttype=core&format=json

Current Treatment Options in Oncology

20 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22241590%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

volume

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22241590%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22241590%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

page(s)

122-136

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22241590%20AND%20SRC:MED&resulttype=core&format=json

Reticulum Cell Sarcoma after Renal Homotransplantation and Azathioprine and Prednisone Therapy

20 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0177-X

Identifying the patient at risk for post-transplant lymphoproliferative disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0177-X

Post-transplant lymphoproliferative disorders occurring after renal transplantation in adults: report of 230 cases from the French Registry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0177-X

Posttransplant lymphoproliferative disease in liver transplant patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0177-X

Identification of prognostic factors in 61 patients with posttransplantation lymphoproliferative disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0177-X

Prognostic analysis for survival in adult solid organ transplant recipients with post-transplantation lymphoproliferative disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0177-X

Risk factors for posttransplant lymphoproliferative disorder (PTLD) in pediatric kidney transplantation: a report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0177-X

Posttransplant lymphoproliferative disorders after renal transplantation in the United States in era of modern immunosuppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0177-X

Post-transplantation lymphoproliferative disorders: diagnosis, prognosis, and current approaches to therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0177-X

Post-transplant lymphoproliferative disorder: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0177-X

Impact of Epstein-Barr virus in monomorphic B-cell posttransplant lymphoproliferative disorders: a histogenetic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0177-X

Epstein-Barr virus-induced posttransplant lymphoproliferative disorders. ASTS/ASTP EBV-PTLD Task Force and The Mayo Clinic Organized International Consensus Development Meeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0177-X

Epstein-Barr Virus-related post-transplant lymphoproliferative disorders: pathogenetic insights for targeted therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0177-X

Incidence of PTLD in pediatric renal transplant recipients receiving basiliximab, calcineurin inhibitor, sirolimus and steroids.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0177-X

American Society of Transplantation recommendations for screening, monitoring and reporting of infectious complications in immunosuppression trials in recipients of organ transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0177-X

Association of HLA polymorphisms with post-transplant lymphoproliferative disorder in solid-organ transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0177-X

Association of human leukocyte antigen haplotypes with posttransplant lymphoproliferative disease after solid organ transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0177-X

Natural killer-cell receptor polymorphisms and posttransplantation non-Hodgkin lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0177-X

Use of cytokine polymorphisms and Epstein-Barr virus viral load to predict development of post-transplant lymphoproliferative disorder in paediatric liver transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0177-X

Evidence for genetic susceptibility towards development of posttransplant lymphoproliferative disorder in solid organ recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0177-X

Tumour necrosis factor gene polymorphism: a predictive factor for the development of post-transplant lymphoproliferative disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0177-X

Racial variation in the development of posttransplant lymphoproliferative disorders after renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0177-X

Lymphoproliferative disorders in heart transplant recipients: role of hepatitis C virus (HCV) and Epstein-Barr virus (EBV) infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0177-X

Posttransplant lymphoproliferative disease in primary Epstein-Barr virus infection after liver transplantation: the role of cytomegalovirus disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0177-X

T-cell and NK-cell posttransplantation lymphoproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0177-X

Diagnosis of post-transplant lymphoproliferative disorder in solid organ transplant recipients - BCSH and BTS Guidelines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0177-X

Lymphoproliferative disorders after solid organ transplantation-classification, incidence, risk factors, early detection and treatment options

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0177-X

Epstein-Barr virus-negative post-transplant lymphoproliferative disorders: a distinct entity?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0177-X

Posttransplant lymphoproliferative disorders not associated with Epstein-Barr virus: a distinct entity?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0177-X

Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: outcomes and prognostic factors in the modern era.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0177-X

Posttransplantation lymphoproliferative disorders in solid organ recipients are predominantly aggressive tumors of host origin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0177-X

Posttransplant lymphoproliferative disorder: significance of central nervous system involvement

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0177-X

Primary central nervous system post-transplantation lymphoproliferative disorder: an International Primary Central Nervous System Lymphoma Collaborative Group Report

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0177-X

Prevention and preemptive therapy of postransplant lymphoproliferative disease in pediatric liver recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0177-X

Ganciclovir and acyclovir reduce the risk of post-transplant lymphoproliferative disorder in renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0177-X

A phase 1/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0177-X

Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0177-X

Reduction in immunosuppression as initial therapy for posttransplant lymphoproliferative disorder: analysis of prognostic variables and long-term follow-up of 42 adult patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0177-X

Reduction of immunosuppression as initial therapy for posttransplantation lymphoproliferative disorder(★).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0177-X

Prognostic factors in patients with post-transplant lymphoproliferative disorders (PTLD) in the rituximab era.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0177-X

Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0177-X

Treatment of PTLD with rituximab or chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0177-X

Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder: a retrospective analysis on 32 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0177-X

Rituximab (chimeric anti-CD20 antibody) for posttransplant lymphoproliferative disorder after solid organ transplantation in adults: long-term experience from a single center.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0177-X

Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0177-X

Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0177-X

Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0177-X

Long-term survival in post-transplant lymphoproliferative disorders with a dose-adjusted ACVBP regimen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0177-X

Fludarabine, cyclophosphamide, doxorubicin (FCD), and rituximab: a remission induction therapy for aggressive pediatric post-transplant lymphoproliferative disease (PTLD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0177-X

Durable remission after aggressive chemotherapy for very late post-kidney transplant lymphoproliferation: A report of 16 cases observed in a single center.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0177-X

Mini-BEAM and autologous hematopoietic stem-cell transplant for treatment of post-transplant lymphoproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0177-X

Efficacy and tolerability of high-dose methotrexate in central nervous system positive or relapsed lymphoproliferative disease following liver transplant in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0177-X

Lymphoma after solid organ transplantation: risk, response to therapy, and survival at a transplantation center.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0177-X

Lymphomas occurring late after solid-organ transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0177-X

Post-transplant lymphoproliferative disorder subtypes correlate with different recurring chromosomal abnormalities

21 January 2018

1 reference

12 December 2020

Malignant neoplasms following bone marrow transplantation.

1 reference

12 December 2020

A gene polymorphism associated with posttransplant lymphoproliferative disorder

1 reference

12 December 2020

Lymphomas after solid organ transplantation: a collaborative transplant study report

1 reference

12 December 2020

Epstein-Barr virus (EBV) load in bone marrow transplant recipients at risk to develop posttransplant lymphoproliferative disease: prophylactic infusion of EBV-specific cytotoxic T cells.

1 reference

12 December 2020

Interferon gamma (IFN-gamma) polymorphism in posttransplantation lymphoproliferative disease

1 reference

12 December 2020

Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial.

1 reference

12 December 2020

Interferon-alpha treatment of posttransplant lymphoproliferative disorder in recipients of solid organ transplants

1 reference

12 December 2020

Early steroid withdrawal in pediatric renal transplant: five years of follow-up

1 reference

12 December 2020

Autologous bone marrow transplantation for cyclosporin-related lymphoma in a renal transplant patient

1 reference

12 December 2020

Incidence of non-Hodgkin lymphoma in kidney and heart transplant recipients

1 reference

12 December 2020

CHOP-21 for the treatment of post-transplant lymphoproliferative disorders (PTLD) following solid organ transplantation

1 reference

12 December 2020

Associations of Human Leukocyte Antigen (HLA) haplotypes with risk of developing lymphoproliferative disorders after renal transplantation

1 reference

12 December 2020

Prospective phase II trial of extended treatment with rituximab in patients with B-cell post-transplant lymphoproliferative disease

1 reference

12 December 2020

Central nervous system lymphomas in organ allograft recipients

1 reference

12 December 2020

Epstein-Barr virus associated B cell lymphoproliferative disorders following bone marrow transplantation

1 reference

12 December 2020

Treatment of B-lymphoproliferative disorder with a monoclonal anti-interleukin-6 antibody in 12 patients: a multicenter phase 1-2 clinical trial

1 reference

12 December 2020

CNS or bone marrow involvement as risk factors for poor survival in post-transplantation lymphoproliferative disorders in children after solid organ transplantation

1 reference

12 December 2020

Anti-B-cell monoclonal antibody treatment of severe posttransplant B-lymphoproliferative disorder: prognostic factors and long-term outcome.

1 reference

12 December 2020

Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients.

1 reference

12 December 2020

Lymphomas occurring late after solid-organ transplantation: influence of treatment on the clinical outcome

1 reference

12 December 2020

Epstein-Barr virus lymphoproliferation after bone marrow transplantation.

1 reference

12 December 2020

HLA antigens and post renal transplant lymphoproliferative disease: HLA-B matching is critical

1 reference

12 December 2020

Histogenetic phenotypes of B cells in posttransplant lymphoproliferative disorders by immunohistochemical analysis correlate with transplant type: solid organ vs hematopoietic stem cell transplantation

1 reference

12 December 2020

Aggressive treatment for postcardiac transplant lymphoproliferation

1 reference

12 December 2020

Clinical and pathological prognostic markers for survival in adult patients with post-transplant lymphoproliferative disorders in solid transplant

1 reference

12 December 2020

Successful treatment of a child with late-onset T-cell post-transplant lymphoproliferative disorder/lymphoma

1 reference

12 December 2020

The clinicopathologic spectrum of posttransplantation lymphoproliferative disorders

1 reference

12 December 2020

Successful treatment of posttransplant lymphoproliferative disorder in a renal transplant patient by autologous peripheral blood stem cell transplantation

1 reference

12 December 2020

10.1007/S11864-011-0177-X

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22241590%20AND%20SRC:MED&resulttype=core&format=json

release_n6mcrxpggnhyxcu3kmkr4ft7li

20 January 2020

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/n6mcrxpggnhyxcu3kmkr4ft7li

24 November 2022

mapped directly with Wikidata item

1 reference